We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.
Health conditions and diseases that the clinical trial is designed to study and treat.
Hormone receptor positive, HER2 negative metastatic breast cancer (HR+ HER2- MBC) is a type of breast cancer that grows in response to hormones and does not have excess HER2 protein. This condition can spread to other parts of the body and may require specific treatments.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
